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Abstract
ALS8 is caused by a dominant mutation in an evolutionarily conserved protein, VAPB (vesicle-associated membrane protein
(VAMP)-associated membrane protein B)/ALS8). We have established a fly model of ALS8 using the corresponding mutation
in Drosophila VAPB (dVAP33A) and examined the effects of this mutation on VAP function using genetic and morphological
analyses. By simultaneously assessing the effects of VAP
wt and VAP
P58S on synaptic morphology and structure, we
demonstrate that the phenotypes produced by neuronal expression of VAP
P58S resemble VAP loss of function mutants and
are opposite those of VAP overexpression, suggesting that VAP
P58S may function as a dominant negative. This is brought
about by aggregation of VAP
P58S and recruitment of wild type VAP into these aggregates. Importantly, we also demonstrate
that the ALS8 mutation in dVAP33A interferes with BMP signaling pathways at the neuromuscular junction, identifying a
new mechanism underlying pathogenesis of ALS8. Furthermore, we show that mutant dVAP33A can serve as a powerful
tool to identify genetic modifiers of VAPB. This new fly model of ALS, with its robust pathological phenotypes, should for
the first time allow the power of unbiased screens in Drosophila to be applied to study of motor neuron diseases.
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Introduction
Amyotrophic lateral scelerosis (ALS) is a progressive neurode-
generative disease characterized by loss of motor neurons in the
spinal cord (‘‘lower’’ motor neurons), brainstem, and cortex
(‘‘upper’’ motor neurons). The combination of muscular atrophy
and fasciculations secondary to lower motor neuron loss, as well as
spasticity due to upper motor neuron death, gives rise to the
characteristic clinical picture of the disorder [1]. Recently, Zatz
and coworkers identified a new locus for ALS/motoneuron disease
at 20q13.3 (ALS8) in a large Brazilian family [2]. ALS8 is an
autosomal dominant slowly progressive disorder characterized by
fasciculation, cramps, and postural tremor. Autonomic abnormal-
ities are also seen [3]. ALS8 is caused by a missense mutation in
the vesicle-associated membrane protein (VAMP)/ synaptobrevin-
associated membrane protein B gene (VAPB) [2].
VAPB is a type II integral membrane protein comprised of an
amino terminal major sperm protein (MSP) domain that bears
22% sequence identity to the major sperm protein, a central
coiled-coil domain, and a membrane anchored carboxy terminal
domain [4,5]. This protein is phylogenetically well conserved;
homologs of VAPB are found across species from yeast to
mammals [2,6,7]. Several different functions of VAP are known. A
conserved function involves recruitment of FFAT motif containing
proteins to the ER [6,8]. In addition, VAP has a proposed role in
vesicle trafficking [9,10]. In yeast, Scs2, the yeast homolog of VAP,
plays a role in the transcriptional regulation of the INO1 gene,
which is important for the synthesis of inositol [11]. In Drosophila,
dVAP33A, the fly homolog of VAPB (hereafter referred to as
VAP), binds to the microtubule network and regulates bouton size
at the neuromuscular junction [12].
The ALS8-associated missense mutation occurs in the con-
served MSP domain of VAPB. The mutation appears to alter the
protein’s subcellular distribution in vitro, with the mutant failing to
colocalize with ER or Golgi markers and forming intracytoplasmic
aggregates [2]. Subsequent biochemical studies have demonstrated
a role for VAPB in the unfolded protein response (UPR); the ALS8
mutation impairs the function of the wild type protein in the UPR
[13]. More recently, Hoogenraad and colleagues have demon-
strated VAPA and VAPB are reduced in ALS patients and in
mutant SOD1 transgenic mice, suggesting a wider role for VAPB
in sporadic and familial forms of ALS [14].
Here, we have used Drosophila to study the effect of the ALS8-
associated mutation using fly VAP. We demonstrate that, unlike
the wild type protein, misexpression of the ALS-associated VAP
mutation has phenotypic effects reminiscent of loss of function
mutations in the endogenous gene. The mutant protein aggre-
gates, is ubiquitinated, recruits wild type protein into aggregates,
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negative mechanism. Importantly, we find that expression of the
mutant protein interferes with BMP signalling at the neuromus-
cular junction, which not only suggests a possible regulation of this
pathway by VAP, but also could have implications in understand-
ing disease pathogenesis. This model thus provides a novel
platform for genetic dissection of motor neuron death that may
provide powerful insights into both sporadic and familial ALS.
Results
Expression of VAP
P58S Impairs VAP Activity In Vivo
In order to understand how the ALS8-associated mutation
affects VAP function and other cellular processes, we used a gain
of function approach. We generated transgenic flies carrying the
wild type (VAP
wt) and mutant (VAP
P58S) forms of VAP using the
GAL4-responsive UAS expression construct [15]. As a first step,
we expressed both constructs in a variety of tissues using different
GAL4 driver lines and examined the effect of each on viability of
the organism. These included neuronal (elav), glial (repo), muscle/
mesoderm (24B), and ubiquitous drivers (tubulin and actin;
Table 1). Overexpression of VAP
wt in muscle using 24B-GAL4
[15] was lethal during early larval life (first or second instar). When
expression was carried out using a more restricted GAL4 line,
G14-GAL4 [16], the animals were able to survive through pupal
development but were unable to eclose from their pupal cases and
died as pharate adults. In contrast to wild type, overexpression of
VAP
P58S in muscle was not lethal; viable adult flies were obtained
at 25uC (Table 1). However, at 30uC, expression of mutant VAP
in muscle was lethal; the animals died during the pupal stage
(Table 1). Surprisingly, neuronal expression of neither VAP
wt nor
VAP
P58S had any effect on viability at either temperature.
To ensure that their differential effects were not due to
differences in the expression level of VAP
wt and VAP
P58S
transgenes, we performed an immunoblot analysis. Both trans-
genes were found to have comparable levels of protein expression
(Figure S1). These data suggest that the ALS8 mutation impairs
the biological activity of VAP such that higher expression of the
mutant protein is required to bring about effects similar to those
elicited by the wild type protein.
It has been previously reported that VAP regulates bouton size
at the neuromuscular junction in a dose-dependent manner [12].
Increased expression of VAP leads to smaller and more numerous
boutons whereas, reduced VAP expression results in fewer but
larger boutons. We therefore examined the effect of neuronal
overexpression of VAP
P58S on bouton morphology at the third
instar larval neuromuscular junction. Consistent with the findings
of Bellen and coworkers [12], we found that expression of VAP
wt
using the pan-neuronal elav-GAL4 or the more restricted OK6-
GAL4 driver [16] produced smaller boutons (Figure 1B and E). In
contrast, animals overexpressing VAP
P58S had larger boutons
(Figure 1C and F).
We measured and compared bouton size of control and animals
overexpressing VAP
wt and VAP
P58S by calculating the average
diameter of boutons on muscle 4. Only the largest diameter of each
bouton was measured in each case. The average bouton diameter of
at least 15 synapses was calculated for each of the genotypes. Pan-
neuronal expression of VAP
P58S caused a small but significant
increase inbouton sizeascompared tocontrol animalsand wildtype
overexpressors (Figure 1G). Similar results were obtained with the
OK6-GAL4 (Figure 1G). As described previously [12], we also
observed an increase in bouton number with neuronal expression of
wild type VAP. However, overexpression of mutant VAP had no
effect on bouton number as compared to control (data not shown).
Interestingly, overexpression of VAP in neurons altered the staining
pattern of Discs large (DLG), which labels the subsynaptic reticulum
(SSR)onthe postsynapticsurface.Unlikewildtype,DLGstaining in
these animals appeared broad and diffuse (data not shown),
indicating that neuronal expression of VAP can influence the
organization of post-synaptic elements, consistent with a non cell
autonomous action of VAP.
Next,weexaminedtheeffectsofexpressionofVAP
P58Sonbouton
size in Drosophila mutants that lack full-length endogenous VAP
protein. We expressed VAP
wt and VAP
P58S in the CNS of the
VAP
D166 mutant. This mutant is a partial loss- of- function allele of
VAP that lacks approximately 100 residues at the amino terminal
region of the protein. Hemizygous VAP
D166 males survive until the
third instar larval stage, but most of them die as pupae and very few
‘‘escaper’’ males are observed on eclosion [12]. Similar to VAP null
mutants, VAP
D166 larvae have enlarged boutons at the larval
neuromuscular junction, and this phenotype was rescued by
neuronal expression of wild type VAP (Fig 1I). However, we were
unabletorescue thisphenotype with VAP
P58S(Fig1J). Wemeasured
the average bouton size in all three genotypes: the mean bouton
diameter inVAP
D166 maleswas 6.1860.15 mm(F ig ur eHan dK) .In
the presence of neuronally expressed wild type VAP, however, these
boutons were significantly smaller, having an average diameter of
4.8960.13 mm (Figure 1I and K), similar to the size observed in
control animals (Fig 1G, blue bar). In contrast, neuronal expression
ofVAP
P58S inVAP
D166 mutantsdid notcauseanysignificant change
inboutonsize(5.9060.24 mm;Figure1Jand K).Thus,expressionof
wild type but not mutant VAP was able to rescue the enlarged
bouton phenotype in dVAP
D166 mutants.
VAP
P58S May Function as a Dominant Negative
The inability of VAP
P58S to rescue the bouton phenotype
associated with VAP
D166 shows that the ALS8-associated missense
mutation impairs VAP function. This, together with the observation
that neuronal expression of VAP
P58S increases bouton size similar to
VAP loss of function, suggests that the mutation might function as a
dominant negative. To explore this possibility, we compared the
ability of VAP
wt and VAP
P58S to rescue the lethality associated with
VAP loss of function. Since neuronal expression of VAP is sufficient
to rescue lethality [12], we used elav-GAL4 to express VAP
wt and
VAP
P58S transgenes in genetic backgrounds containing two
independent VAP mutations: VAP
D20 (a null allele) and VAP
D166.
Males hemizygous for these mutations do not survive to eclosion as
adults. In both cases, the percentage of mutant VAP hemizygous
males that eclosed as adults was higher with VAP
wt as compared to
VAP
P58S (Figure 2A). The rescue by VAP
wt was approximately 63%
and 33% greater as compared to VAP
P58S in VAP
D20 and VAP
D166
backgrounds, respectively. Of note, when VAP
wt and VAP
P58S were
coexpressed, the percentage of rescued males that eclosed was very
similar to that observed with VAP
P58S alone, suggesting that the
Table 1. A comparison of the effects of overexpression of
VAP
wt and VAP
P58S in various tissues X, lethality.
elav-GAL4 24B-GAL4 tub-GAL4 act-GAL4 repo-GAL4
25u 30u 25u 30u 25u 30u 25u 30u 25u 30u
VAP
wt !! 666 6 6ND ! ND
VAP
P58S !! ! 6 ! 6 ! ND ! ND
Check, viable. ND, not done.
doi:10.1371/journal.pone.0002334.t001
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protein, consistent with a dominant negative mode of action
(Figure 2A).
We were intrigued by the apparent inhibition of normal neuronal
VAP function by the ALS8 mutation and sought to examine the
consequences of this putative dominant negative interaction in a
different neuronal context. Overexpression of neurotoxic genes
including mutant ataxin-1 in sensory precursors using the scabrous-
GAL4 driver leads to loss of bristles in the adult [17]. We found that
overexpression of VAP
wt using scabrous-GAL4 resulted in failure of
thoracic macrochaetae to develop (Figure 2C). This bristle loss was
not observed in sca-GAL4/UAS-VAP
P58S animals (Figure 2D).
However, coexpression of VAP
P58S with VAP
wt suppressed the
bristle phenotype associated with the latter (Figure 2E), again
supporting a dominant negative effect of VAP
P58S.
VAP
P58S Appears to Aggregate and Recruit Normal VAP
into Aggregates In Vivo
Abnormal aggregation of cellular proteins is a common feature
of many neurodegenerative diseases, including Alzheimer’s,
Huntington’s, and Parkinson’s diseases, prion disorders, and
ALS [18–22]. Biochemical studies have demonstrated that the
ALS8 mutation results in insolubility and aggregate formation of
VAPB in non-ER fractions [2,13,14]. To test if VAP
P58S formed
aggregates similar to the human mutant VAPB protein, we
compared the cellular distribution of wild type and ALS8 mutant
VAP in the muscle of third instar larvae because of the ease with
which this tissue can be visualized. Expression of VAP
wt resulted in
a uniform increase in the intensity of VAP staining throughout the
muscle (Figure 3B); on the other hand, expression of VAP
P58S
resulted in a more punctate appearance in muscle (Figure 3C). To
Figure 1. VAP
wt and VAP
P58S (VAPmut) have differential effects on synaptic morphology at the neuromuscular junction. Shown are
representative synapses on muscle 4 of 3
rd instar larvae stained with anti-HRP, which labels the presynaptic membrane. The effect of neuronal
overexpression of VAP
wt and VAP
P58S on bouton morphology was assessed using the pan-neural elav-GAL4 driver (A–C) and the more restricted OK6-
GAL4 (D–F). (H–J) Effect of neuronal expression of wild type and mutant VAP on bouton size in VAP
D166 animals. (A and D) Control synapses on
muscle 4 (elav-GAL4/+ and OK6-GAL4/+ respectively). Neuronal overexpression of VAP
wt results in smaller boutons (B and E), while expression of
VAP
P58S leads to an increase in bouton size (C and F). (G). Graphical analysis of bouton size effects. Here and throughout, values shown are
mean6SEM. For both drivers, the average size of boutons in animals expressing VAP
wt and VAP
P58S was found to be significantly different not only
with respect to one other but also controls (*, p,0.001, one way ANOVA with Sidak-Holm multiple comparison test). The bouton sizes measured was
as follows (mm): elav-GAL4/+=4.0360.14 (n=16); elav-GAL4/VAP
wt=2.7960.17 (n=16); elav-GAL4/ VAP
P58S=4.4560.08 (n=24); OK6-GAL4/
+=4.2460.14 (n=20); OK6-GAL4/VAP
wt=2.7860.17 (n=11); OK6-GAL4/ VAP
P58S=4.7260.11 (n=24). (H–J) A representative synapse on muscle 4
is shown in each panel. (H) In VAP
D166 mutants, enlarged boutons are observed. (I) Neuronal expression of VAP
wt using elav-GAL4 rescues this
phenotype by reducing bouton size. (J) Expression of VAP
P58S had no effect on bouton size. (K) Histogram comparing bouton size for the genotypes
in panels H–K. Mean bouton diameter (mm) for VAP
D166;UAS-VAP
wt/elav-GAL4 (4.8960.13 (n=27)) was significantly different from VAP
D166 (6.1860.15
(n=24); p,0.001, one way ANOVA with Sidak-Holm comparison). However, bouton size in VAP
D166;UAS-VAP
P58S/elav-GAL4 (5.960.24 (n=30) did not
differ significantly from VAP
D166 . n.s., not significant. Scale bar, 10 mm.
doi:10.1371/journal.pone.0002334.g001
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P58S appears to function as a dominant negative by inhibiting the activity of wild type VAP. (A) Histogram comparing the
rescue from lethality of VAP
D20 (null mutant) and VAP
D166 (partial deletion), using neuronal expression of VAP
wt,V A P
P58S, or a combination of both. The
ordinate represents the percentage of mutant hemizygous males obtained (i.e., VAP mutant hemizygous males/VAP mutant hemizygous males+balancer
chromosome males). Each bar represents the mean obtained from at least 2–3 independent experiments. Both VAP
P58S and VAP
wt are able to rescue the
larval lethality observed in VAP
D20 and VAP
D166 mutants. However, the percentage of mutant males obtained with VAP
wt is higher (72.967.3 for VAP
D20
and 61.561.2 for VAP
D166) as compared with VAP
P58S (45.063.1 for VAP
D20 and 46.660.06 for VAP
D166). For each mutant, the value for wild type rescue
differed significantly from mutant (p,0.05 for. D20 and 0.01 for D166; ANOVA with Sidak-Holm test). Rescue of lethality is also obtained by co-expressing
VAP
P58S and VAP
wt. In this case, the percentage of mutant males obtained was similar to that observed with VAP
P58S alone (45.763.3 for VAP
D20 and
40.362.7 for VAP
D166). However, for each mutant, rescue using the recombined VAP
P58S,V A P
wt chromosome differed significantly from that obtained
using VAP
wt alone (p,0.05 for D20 and 0.01 for D166, ANOVA with Sidak-Holm test). n.s., not significant. (B–E) VAP
P58S suppresses the thoracic bristle
phenotype produced by expression of VAP
wt using Sca-GAL4. (B) Shown in this panel is the thorax of a control (sca-GAL4/+) adult fly with a stereotyped
pattern and number of dorsal macrochaetae (arrows). (C) In Sca-GAL4/UAS-VAP
wt animals, the dorsal macrochaetae either fail to develop or are
dramatically reduced in number. (D) Expression of VAP
P58S has no effect onthe development or number of bristles. (E) However, co-expression of VAP
P58S
with VAP
wt results in a suppression of the bristle loss phenotype caused due to overexpression of VAP
wt.
doi:10.1371/journal.pone.0002334.g002
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cellular context, we also examined the cellular distribution of
VAP
wt and VAP
P58S in neurons of third instar larvae. As in
muscle, neurons overexpressing VAP
P58S showed punctate
cytoplasmic staining with reduced staining at the cell membrane,
whereas more evenly distributed cytoplasmic staining was
observed in neurons overexpressing VAP
wt (Figure S2).
Cellular deposits containing ubiquitin are characteristic of a
number of neurodegenerative disorders, including ALS [23,24].
We therefore examined ubiquitin staining in animals expressing
Figure 3. VAP
P58S forms ubiquitinated aggregates and induces aggregation of VAP
wt in vivo. (A–C) Confocal images of 3
rd instar larval
muscles stained with anti-VAP. (A) A control animal (G14-GAL4/+). VAP expression is observed at the neuromuscular junction and in underlying
muscles 6 and 7. (B) G14-GAL4/UAS-VAP
wt. Increased VAP immunoreactivity is observed with expression of VAP
wt. (C) G14-GAL4/UAS-VAP
P58S.
Punctate staining of ALS-associated mutant VAP is observed. (D) Staining with anti-VAP (red) and anti-ubiquitin (Ubi; green) of animals expressing
VAP
P58S in the muscle. Mutant VAP forms aggregates that appeared as puncta through out the muscle (red). Ubiquitin immunoreactive puncta also
are observed (green) that largely colocalized with the VAP aggregates (merged image). (E–G) Staining with anti-myc (green) and anti-HA (red) of
animals expressing myc-VAP
wt and HA-VAP
P58S in the muscle. (E) Similar to untagged VAP
wt and VAP
P58S transgenes, expression of myc-VAP
wt
appears diffuse and cytoplasmic. (F) HA-VAP
P58S forms aggregates that appear punctate throughout the muscle. (G) Muscle field of a 3
rd instar larva
expressing both myc-VAP
wt and HA-VAP
P58S. Expression of myc-VAP
wt (green) appears punctate and colocalizes with HA-VAP
P58S aggregates (merged
image). Scale bar, 20 mm.
doi:10.1371/journal.pone.0002334.g003
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wt and VAP
P58S. In VAP
wt overexpressors, ubiquitin staining
was similar to controls (data not shown). On the other hand, in
animals overexpressing VAP
P58S, punctate ubiquitin immunore-
activity was observed throughout the muscle. These puncta
colocalized with VAP
P58S aggregates, suggesting that mutant
VAP aggregates are ubiquitinated to be targeted for proteosomal
degradation (Figure 3D).
One potential pathogenic mechanism underlying the ALS8
mutation would be recruitment of normal endogenous VAP into
aggregates, thereby depleting the cell of wild type protein. To test
this possibility, we generated transgenic flies carrying amino
terminal hemagglutinin (HA) and Myc-tagged versions of VAP
P58S
and VAP
wt, respectively. These constructs were tested individually
by expressing transgenes in muscle and staining with the
appropriate epitope tag antibodies. Similar to the untagged form,
Myc-VAP
wt staining was localized to the muscle membrane,
whereas the HA-VAP
58S immunoreactivity appeared punctate
throughout the muscle, suggesting that the tagged versions behave
similar to the untagged forms (Figure 3E and F). However, when
the two transgenes were expressed together, the Myc-VAP
wt
staining appeared more punctate and largely colocalized with the
HA immunoreactive puncta representing the ALS8 mutant VAP
(Figure 3G). These data suggest that VAP
P58S may recruit the wild
type protein into aggregates, consistent with a dominant negative
effect whereby the normal protein thus recruited is functionally
inhibited.
VAP
P58S Impairs Microtubule Organization
Impaired microtubule organization and microtubule dependent
transport are believed to be a common underlying feature in many
neurodegenerative diseases [25]. Microtubule-based transport
plays a crucial role in survival of motor neurons in particular.
Aberrant axonal transport contributes toward pathogenesis in
sporadic ALS and in mice expressing mutant SOD1 [26–28].
Investigators previously have shown that VAP associates with
microtubules [10,12]. In the absence of VAP, microtubule
organization at the neuromuscular junction is abnormal in
Drosophila [12]. We were therefore interested in examining the
effect of VAP
P58S on microtubule organization. We examined the
neuromuscular junction in larvae expressing wild type and mutant
VAP by immunohistochemistry using the monoclonal antibody
22C10, which recognizes Futsch, a presynaptic microtubule-
associated protein related to vertebrate MAP1B [29]. The pattern
of Futsch staining at the neuromuscular junction has been
extensively characterized [12,30–32]. In wild type larvae, Futsch
staining (Figure 4A–D, green) in most boutons appears thread-like,
running along the axis of each synaptic branch and continuous
with the axonal cytoskeleton (Figure 4A, arrow; also see inset). At
distal boutons, Futsch staining appears punctate or diffuse
(Figure 4A, arrowhead; also see inset ). Occasionally, Futsch
staining is found to fill the entire presynaptic space. These two
forms of staining, i..e, ‘‘diffuse’’ and ‘‘filled’’, have been described
as two variant forms of disorganized microtubules found in
mutants affecting synaptic architecture [30,32]. In dVAP null
mutants, approximately 70% of the boutons have been reported to
show a filled (Figure 4B, asterisk) or diffuse pattern of Futsch
immunoreactivity, consistent with reported microtubule disorga-
nization [12]. To determine if expression of VAP
P58S also leads to
disorganization of microtubules, we compared the pattern of
Futsch staining at the neuromuscular junction of larvae expressing
wild type and ALS8 mutant VAP in neurons. Similar to controls,
in animals overexpressing VAP
wt, the microtubules were well
organized; 22C10 staining in most boutons was continuous, with
few boutons displaying a diffuse or filled pattern of Futsch staining
as compared to controls (Figure 4C and E; 33% in controls and
37% in VAP
wt overexpressors). In contrast, expression of VAP
P58S
increased microtubule disorganization: 53% of boutons displayed
either the filled or diffuse pattern of Futsch staining (Figure 4D and
E). This finding was comparable to that observed in VAP
D166
mutants, in which approximately 63% of the boutons showed
disorganized microtubules (Figure 4E). Thus, microtubule organi-
zation is impaired by expression of ALS associated mutant VAP.
Overexpression of VAP
wt But Not VAP
P58S Leads to a
Decrease in the Number of Active Zones at the
Neuromuscular Junction
Having established a putative dominant negative role for
VAP
P58S, we were interested in determining whether its expression
in neurons altered the expression or localization of other synaptic
proteins at the neuromuscular junction. Therefore, larvae
expressing wild type and ALS8 mutant VAP were stained with
antibodies against a variety of synaptic proteins such as
synaptotagmin, syntaxin, and CSP. No obvious defects in the
expression or localization of any of these markers were apparent
(data not shown). However, some differences were observed when
these animals were stained with nc82, a monoclonal antibody
which recognizes Bruchpilot (brp), a crucial component found in
active zones at the synapse [33,34]. Despite an increase in the total
number of boutons as a result of overexpression of VAP
wt, there
were fewer nc82 immunoreactive puncta per synapse in these
animals (Figure 5B and D). Quantification of the total number of
nc82 puncta per synapse at muscle 4 for each of the genotypes
revealed a significant decrease in wild type overexpressors as
compared to mutant and control larvae. No significant differences
in the number of nc82 immunoreactive puncta were observed
between controls and larvae expressing VAP
P58S (Figure 5C and
D). To determine if the decrease in the total number of nc82
puncta was an indirect consequence of reduced bouton size caused
by overexpression of VAP
wt, we quantitated the number of the
nc82 positive puncta relative to bouton cross sectional area in all
three genotypes. In this case however, we did not observe any
significant differences between the three genotypes (Table S1).
This analysis suggests that the decrease in the total number of
active zones per synapse might indeed be an effect of reduced
bouton size rather than loss of active zones per se.
Overexpression of VAP
wt and VAP
P58S Causes
Ultrastructural Abnormalities at the Synapse
Studies conducted in mutant SOD1 transgenic mouse models
indicate that loss of synaptic connections, leading to nerve
retraction, are early events in development of pathological
phenotypes [35–37]. To evaluate whether expression of VAP
P58S
causes structural abnormalities that might lead to synaptic
instability, we conducted an ultrastructural analysis of the
neuromuscular junction in VAP
wt and VAP
P58S. At least five
animals of each genotype were used for the analysis. The
ultrastructure of a wild type bouton is shown in Figure 6A;
notable structures include the subsynaptic reticulum (SSR), as well
as the ‘‘T’’ bars associated with active zones (asterisk).
Overexpression of the wild type protein, as previously described
(Figure 1), resulted in smaller boutons and, as previously reported
by Pennetta and coworkers, these boutons also contained
significantly fewer neurotransmitter vesicles [38] (Figure 6B). We
observed a 54% decrease in the number of vesicles per bouton
cross sectional area in these animals (p,0.001). In contrast,
boutons from synapses overexpressing VAP
P58S contained abun-
dant neurotransmitter vesicles, similar to controls (Figure 6C and
Drosophila Model of ALS8
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(Figure 6C and D, dark arrow) and sometimes filled with electron
dense material (Figure 6C, dark arrowhead). We also occasionally
observed abnormal electron dense structures in the SSR of these
animals (Figure 6C and D, white arrowhead). We frequently
observed electron dense structures attached to neurotransmitter
vesicles floating within the cytoplasmic space of boutons and not
associated with the presynaptic membrane (Figure 6D, white
arrow). This phenotype, referred to as ‘‘floating T-bars’’ [39], was
more frequently observed in animals expressing VAP
P58S (44%
boutons in elav-GAL4/UAS-VAP
P58S versus 12.5 % in elav-
GAL4/+ animals). In addition, there was a significant increase in
the number of these floating T-bar structures in animals expressing
VAP
P58S as compared to the controls (0.8160.23 as expressed per
bouton in elav-GAL4/UAS-VAP
P58S versus 0.2560.17 in elav-
GAL4/+ animals; p,0.05; see Table S3). We did not observe this
phenotype in animals overexpressing VAP
wt.
Interaction between VAP and BMP signaling
The phenotype of floating T-bars that was sometimes observed in
boutons of animals expressing VAP
P58S is reminiscent of the
phenotype associated with mutations in components of the bone
morphogenetic protein (BMP) signaling pathway [16,39–41]. Given
the resemblance between this phenotype and mutants of the BMP
pathway, we sought to identify potential perturbations of BMP
signaling in animals expressing the ALS8 mutation. In Drosophila,
BMP signaling at the neuromuscular junction takes place in an
anterograde as well as a retrograde manner and loss of BMP
signaling leads to defects in synaptic growth and function [16,39–
41]. The signaling pathway involves activation of a heteromeric
complex comprised of two type I and two type II receptor molecules.
Upon ligand binding, the type II receptor phosphorylates the type I
receptors, which transduce the signal by phosphorylating receptor-
specific transcription factors called Smads. The phosphorylated
Smad (pMAD in Drosophila) complex with Smad4 (Medea in
Figure 4. VAP
P58S disrupts microtubule organization. Representative synapses on muscle 6–7 of elav-GAL4/+ (A), VAP
D166 (B), elav-GAL4/ UAS-
VAP
wt (C) and elav-GAL4/UAS-VAP
P58S animals stained with anti-HRP to recognize the presynaptic membrane (red) and anti-Futsch (green). Anti-
Futsch labels stable presynaptic microtubules. (A) In control animals, anti-Futsch staining appears thread-like (arrow). At distal boutons, the staining
appears more punctate or diffuse (arrowhead). (B) In VAP
D166 animals, Futsch expression fills up the cytoplasmic region inside boutons (asterisks). (C)
In elav-GAL4/UAS-VAP
wt animals, the anti-Futsch staining appears similar to control animals, although some boutons show disorganized microtubule
morphology (asterisk). (D) In elav-GAL4/UAS-VAP
P58S, more boutons have a disorganized microtubule morphology (asterisk). (E) Quantitation of
microtubule morphology assessed using anti-Futsch. The percentage of boutons of the muscle 6-7 synapse exhibiting disorganized microtubule
phenotypes was calculated. Values: Controls: 34.061.5% (n=26 synapses). elav-GAL4/ UAS-VAP
wt: 37.062.6 % (n=25 synapses). VAP
D166 (63.465.4;
n=15 synapses). elav-GAL4/UAS-VAP
P58S (53.362.1 %; n=40 synapses). The black brackets above the histogram indicate all significantly different
relationships (*, p,0.001, ANOVA with Kruskal-Wallis test). The red brackets indicate non significant relationships. There was no significant difference
in the percentage of boutons with abnormal microtubule morphology between VAP
D166 and elav-GAL4/UAS-VAP
P58S, nor was there a significant
difference between elav-GAL4/UAS-VAP
wt and the control. Scale bar, 20 mm.
doi:10.1371/journal.pone.0002334.g004
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wt but not VAP
P58S leads a reduction in active zones. (A–C) Confocal images of synapses at
muscle 4 stained with anti-HRP (red) and nc82, which labels the active zone protein bruchpilot (brp, green). Control (A) and elav-GAL4/UAS-VAP
P58S
(C) animals showed similar numbers of nc82 immunoreactive puncta per synapse. In contrast, such puncta were fewer in elav-GAL4/UAS-VAP
wt
animals (B). (D) A histogram showing the difference in number of nc82 positive puncta in all 3 genotypes. In elav-GAL4/UAS-VAP
wt animals, an
average of 142614 puncta per synapse were observed (n=18) as compared to 19968.4 (n=17) and 199612 (n=16) in control and elav-GAL4/UAS-
VAP
P58S animals, respectively (*, different from other two genotypes, p,0.001, ANOVA with Sidak-Holm test). n.s., not significant. Scale bar, 10 mm
doi:10.1371/journal.pone.0002334.g005
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target genes [42]. The level of activity of this pathway directly
correlates with the level of phosphorylated Smad/pMAD; therefore,
changes in levels of phosphorylated Smad or pMAD are used assess
the activity of this signaling pathway [43,44]. At the neuromuscular
junction, pMAD accumulates at postsynaptic densities opposite the
presynaptic active zone marker, bruchpilot (nc82) [45]. In motor
neurons, pMAD accumulation takes place in response to retrograde
signaling by the ligand glass bottom boat (gbb), mediated by the type II
receptor wishful thinking (wit)[ 1 6 ] .
In order to assess whether VAP
P58S affects BMP signaling, we
expressed wild type and mutant transgenes in larval muscle using
G14-GAL4 [16] and examined pMAD staining at the neuromus-
cular junction. As reported previously [45], in control animals,
punctate pMAD staining was observed opposite presynaptic active
zones immunostained with nc82 (Figure 7A). In VAP
wt transgenic
animals, pMAD staining was more intense (Figure 7B) and a few
nc82 immunoreactive puncta isolated from pMAD staining were
also observed. In contrast, in animals expressing VAP
P58S, the
intensity of pMAD puncta was decreased (Figure 7C). We
measured the intensity of pMAD puncta in all three genotypes.
As compared to controls, in animals overexpressing VAP
wt we
observed a 40% increase in intensity of pMAD staining, whereas
expression of VAP
P58S resulted in a 42% decrease in intensity of
pMAD staining. In animals expressing VAP
wt, the average relative
pixel intensity was 140.61611.11 (mean6SEM). In VAP
P58S
expressing animals, pixel intensity was 58.3966.60 (mean6SEM).
These values differed significantly (p,0.001 by ANOVA with
Student-Neuman-Keuls test) from control pixel intensities, which
were normalized to 100 (see Materials and Methods). We also
examined pMAD expression in nuclei of motor neurons in the
larval CNS. As at the neuromuscular junction, expression of
VAP
P58S lead to a decrease in the intensity of pMAD staining
(Figure S3), suggesting that both anterograde and retrograde BMP
signaling may be impaired.
These data indicate that increased VAP
wt expression potentiates
BMP signaling, suggesting an interaction between VAP and BMP
signaling pathways. In order to explore this possibility further, we
conducted an epistasis analysis using the bristle phenotype
observed in animals overexpressing VAP
wt. Overexpression of
VAP
wt using sca-GAL4 resulted in loss of thoracic bristles in adult
flies (Figure 8B). To test if VAP and BMP signaling pathways
interact, we co-expressed a dominant negative form of the type I
BMP receptor-thickvein (DN-tkv). We found that co-expression of
DN-tkv suppressed the bristle loss phenotype associated with
overexpression of VAP
wt (Figure 8C). We quantitated this by
Figure 6. Ultrastructural analysis of the neuromuscular junction of animals overexpressing VAP
wt and VAP
P58S. (A–D) Electron
micrographs depicting cross sections of synaptic boutons in control (A), elav-GAL4/UAS-VAP
wt (B), and elav-GAL4/UAS-VAP
P58S larvae (C and D).
Specialized membrane folds present on the postsynaptic surface called the subsynaptic reticulum (SSR), and active zones (asterisks) that include
presynaptic T-bars are indicated. As compared to control boutons (A), boutons from animals overexpressing wild type VAP are smaller and contain
fewer neurotransmitter vesicles (B). Occasionally, fusion of adjacent boutons was observed (arrow). (C and D) Boutons from elav-GAL4/VAP
P58S
animals are shown. In addition to the smaller neurotransmitter containing vesicles, a few large vesicles were observed (C, dark arrow). Electron dense
T-body-like structures associated with clusters of vesicles are often observed within the cytoplasm of the bouton (C, white arrow and inset). Abnormal
electron dense structures are also found in the SSR close to the post-synaptic membrane (C and D, white arrowhead; inset in D).
doi:10.1371/journal.pone.0002334.g006
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PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2334counting the number of bristles present within a defined region of
the thorax of adult flies. In control animals, the ten dorsal
macrochaetae present in this region (circle in Figure 8A) were
invariant in number and position in all adult flies examined
(Figure 8D). However, in flies overexpressing VAP
wt, an average of
only 2–3 bristles were observed. Co-expression of DN-tkv using 2
independently derived transgenic lines resulted in significant
suppression of the bristle loss phenotype: on average, 5–6 bristles
were observed in these flies (Figure 8D). Taken together, these
results are consistent with the assertion that VAP
P58S interferes
with BMP signaling at the neuromuscular junction.
Discussion
We have used Drosophila as a model system to gain insight into
the mechanism by which the ALS8 associated mutation gives rise
to disease. The evolutionary conservation of VAP and the
availability of a vast array of genetic tools make the fly a
particularly attractive model system with which to dissect
pathophysiological mechanisms underlying ALS8. We have
compared and assessed the cellular consequences of expression
of wild type and ALS8-associated mutant VAP on the develop-
ment and function of the synapse at the neuromuscular junction.
In Drosophila, the synapses at the neuromuscular junction are
glutamatergic, providing some similarities to the spinal cord
synapse which are affected in ALS patients. Furthermore, the
presynaptic neurons are obviously the functional equivalent to the
lower motor neurons also affected in ALS patients.
The relationship between mutation and pathogenesis in
inherited neurodegenerative disorders is obviously of great interest
as it could point towards a mechanistic understanding of the
disease and indicate treatment strategies. For genetically dominant
Figure 7. VAP
P58S impairs BMP signalling at the synapse. A–C, representative confocal images of the synapse at muscle 6–7 stained with
phosphorylated SMAD (pMAD; red) and bruchpilot (nc82, green), a component of the active zone. (A) In control animals (G14-GAL4/+) postsynaptic
expression of pMAD coincides with the expression of presynaptic Bruchpilot as shown in the merged image. (B) In G14-GAL4 /UAS-VAP
wt synapses,
more intense pMAD staining is observed, indicative of enhanced BMP signalling. (C). In G14-GAL4/UAS-VAP
P58S animals, pMAD immunoreactive
puncta are less intense (arrow) as compared to the controls indicating reduced BMP signaling. Scale bar, 10 mm.
doi:10.1371/journal.pone.0002334.g007
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haploinsufficiency, and dominant negative effects. Pennetta and
coworkers concluded that the ALS8 mutation is a toxic gain of
function rather than a dominant negative [38]. This conclusion
was based on the toxic properties of the mutant protein in
conjunction with its retention of activity. However, our data and
that of others [13,14] argue against retention of VAP activity by
the ALS8 mutant, but rather suggest that that the ALS8 mutation
in VAMP-associated-protein (VAP) functions through a dominant
negative mechanism. Dominant negative mutations are those in
which the product of the mutant gene adversely affects function of
the normal gene product within the same cell, for example by
forming non-functional dimers. Interestingly, members of the VAP
family are able to form dimers [6,8]. The following experiments
reported here support the notion that the formation of mixed
dimers or aggregates between wild type and ALS8 mutant proteins
is at least in part responsible for the dominant phenotype. The
VAP loss of function phenotype (VAP
D20 and VAP
D166)i s
characterized by an increase in bouton size and increased
microtubule disorganization. Both these phenotypes are observed
when VAP
P58S is overexpressed in neurons, indicating that
expression of the mutant protein is dominant over the wild type
protein. This is not simply due to an excess of mutant protein since
VAP
P58S can also suppress the phenotypes generated by
overexpression of VAP
wt (Figure 4). Finally, VAP
P58S forms
ubiquitinated aggregates that can also recruit and induce
aggregation of wild type protein (Figure 3), thereby rendering it
functionally inactive. The ability of the mutant protein to recruit
and induce aggregation of the wild type protein has also been
reported for mammalian VAP in vitro [13,14]. The finding that
down regulation of mammalian VAP using RNAi techniques is
sufficient to induce cell death in motor neurons [14] also argues
that it is loss of VAP function, rather than the formation of
aggregates, that is pathogenic.
VAP was originally identified as a ‘‘VAMP-associate protein’’ in
Aplysia, and antibodies against VAP decrease synaptic transmission
[10]. Subsequently, VAP was demonstrated to alter the size and
number of boutons at the Drosophila neuromuscular junction [12].
Overexpression of VAP
wt leads to a significant decrease in the total
number of active zone at the synapse despite an increase in bouton
number; fewer nc82 immunoreactive puncta per synapse are
present (Figure 5) even though the number of such puncta per unit
cross sectional area of the bouton (mm
2) is not significantly
different from control and animals expressing mutant VAP.
Further research will be necessary in order to determine whether
this difference in the total number of active zones might lead to
impaired synaptic transmission.
In a recent report, by conducting morophometric analysis on
electron micrographs of individual boutons, Pennetta and
colleagues show that there is no change in the number of active
zones in animals overexpressing VAP
wt in neurons [38]. These
authors also report locomotory defects, synaptic degeneration and
muscle atrophy in larvae expressing VAP
P58S in neurons. We did
not observe any of these defects in our experiments. Differences in
expression levels of the mutant protein could account for these
discrepancies.
Extensive crosstalk between motor neurons and muscle is a
conspicuous feature of neuromuscular junction development in
Drosophila, where synapses must accommodate the increase in size
of muscles during larval development by increasing bouton
number and active zones per bouton. Components of the TGF-
b/ BMP signaling pathway are known to regulate neuronal
survival, synaptic development and function in vertebrates as well
as invertebrates. Recently, reduced TGF-b signaling has been
associated with Alzheimers disease and the level of one of the
receptors (TGFbRII) is reduced in brain tissue of Alzheimer’s
disease patients [46].
In Drosophila, retrograde BMP signaling is required for synaptic
growth at the neuromuscular junction [39]. At the same time,
anterograde BMP signaling in neurons appears to be essential to
restore neurotransmission which is significantly lowered in
mutants of the BMP pathway. Here, we show using epistasis
analysis, the presence of a genetic interaction between VAP and
BMP signaling pathways (Figure 8). We also show that
overexpression of VAP
wt potentiates BMP signaling whereas
overexpression of VAP
P58S impairs BMP signaling as evidenced
by the decrease in intensity of pMAD puncta at the neuromuscular
junction (Figure 7) and nuclei of motor neurons (Figure S3).
Expression of VAP
P58S also causes ultrastructural phenotypes
reminiscent of mutants in the BMP pathway, e.g., floating T-bars
and occasional detached postsynaptic membranes. However, it
should be noted that despite the similarities, these phenotypes are
by no means identical; BMP mutants show smaller synapses (i.e.,
fewer boutons) with no significant change in bouton size- a
phenotype unlike that observed in animals with neuronal
expression of VAP
P58S. This suggests that the aberrations
associated with ALS8 are likely to be more complex than simply
loss of receptors.
Figure 8. Genetic interaction between VAP and BMP signalling:
Expression of dominant negative thickvein suppresses the
VAP
wt bristle phenotype. (A–C) Thoraces of control (A), sca-GAL4/
VAP
wt (B) and sca-GAL4/VAP
wt, DNtkv animals (C). (A) In control animals,
the bristles are invariant in number and position. Circled region
indicates the 10 bristles used for analysis. (B and D) Expression of VAP
wt
using sca-GAL4 leads to loss of bristles. On average, 2–3 bristles are
observed in these animals. (C and D) Expression of dominant negative
thickvein (DN-tkv) results in a significant suppression of the bristle loss
phenotype caused by overexpression of VAP
wt (p,0.001, ANOVA with
Sidak-Holm test). This was observed with two independent lines of DN-
Tkv referred to as L1 and L2; an average of 6 and 5 bristles respectively,
were observed in these animals (D). n.s., not significant.
doi:10.1371/journal.pone.0002334.g008
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mutant SOD transgenic mice [14] suggest a potential role for VAP
in many forms of ALS. Further genetic analysis using this model as
a paradigm for ALS is likely to provide insights into pathways that
contribute to motor neuron dysfunction and death in ALS.
Materials and Methods
Drosophila Genetics and Phenotypic Analysis
The VAP
D166 and VAP
D20 mutant lines and VAP cDNA were
kindly provided by Hugo Bellen. G14-GAL4 and the second
chromosome elav-GAL4 transgenic line were obtained from Kai
Zinn. David Krantz provided the OK6-GAL4 line. The 24B-
GAL4, tubulin-GAL4, actin-GAL4, sca-GAL4, and repo-GAL4
drivers were obtained from the Bloomington stock center. UAS-
tkv
DGSK (UAS-DNtkv) stocks were obtained from Michael
O’Connor; both lines carried two insertions of the transgene [47].
Site-directed mutagenesis using the Stratagene Quick-Change
II kit (Stratagene) was used to generate the P58S mutant using the
wild type cDNA. This manipulation and placement of epitope tags
were performed using the pGEM-7 cloning vector (Promega).
Epitope tags (3X Myc or HA) were engineered at the amino
terminus of wild type and P58S VAP using PCR. Identity of all
constructs was verified by sequencing. Constructs were subcloned
into the UAS expression vector and transgenic flies generated
using standard techniques. Certain lines were generated using
facilities of the Duke Model Systems Genomics Group. Multiple
transgenic lines were generated and tested for each construct. At
least two independently derived lines on the autosomes were tested
for each construct. In no case were insertions selected on the basis
of phenotypes or lack thereof. For all untagged experiments shown
here, we used UAS-VAP
wt-A1.6 and UAS-VAP
P58S-A2.1, which
showed similar elav-GAL4-driven expression levels as assessed
using immunblots of head extracts in combination with guinea pig
anti-VAP (Figure S1). For each construct, each of the lines used
showed the same patterns of lethality under control of various
drivers. Neuronal overexpression with elav-GAL4 was carried out
at 30uC. Experiments involving overexpression in the muscle were
conducted at 25uC. Bristle phenotype and all rescue experiments
were carried out at 23uC.
We generated animals with both HA and myc tags for both the
ALS8 and wild type transgenes in order to exclude the possibility
that aggregation was due to the epitope tag alone (data not shown).
For co-expression studies, mitotic recombination was used to place
both UAS-VAP
wt and UAS-VAP
P58S transgenes on the second
chromosome. For studies of transgene expression in genetic
backgrounds lacking endogenous VAP, VAP
D166 /FM7Kr-GFP;
elav-GAL4 females were crossed to w/Y; UAS-VAP males (either
wild type, P58S, or the recombined chromosome containing both
transgenes).
Immunohistochemistry
Wandering third instar larvae were dissected in PBS and fixed in
Bouin’s fixative (picric acid+37% formaldehyde+glacial acetic acid,
15:5:1) for 10 min for staining using guinea pig anti-VAP and
20 min for all other antibodies. The only exception for fixative was
for experiments using pMAD, in which 4% paraformaldehyde in
PBS was used. The synapse on muscle 4 was used to carry out
bouton size measurement. This muscle receives innervations from 3
motor neurons [48]. However, we examined only the size of type1b
boutons, which show robust Dlg staining. In our experiments, only
synapsespresentinsegmentsA2andA3wereexamined[31].Except
as noted, all antibodies were murine monoclonals obtained from the
Developmental Studies Hybridoma Bank. Primary antibodies used
were anti-HRP (Sigma; 1:500), 22C10 (anti-Futsch; 1:50), NC82
(anti-bruchpilot; 1:50), anti-ubiquitin (FK2, Biomol, 1:500), anti-
Myc (9E10; 1:50), chicken anti-HA (Aves; 1:500), anti-pMAD
(1:500,), rabbit anti-Dlg (1:40,000), 4F3 ( anti-Dlg; 1:50), 8C3 (anti-
Syntaxin; 1:25), and guinea pig anti-VAP (1:200). Anti-VAP was
obtained from Hugo Bellen, Dlg from Vivian Budnik, and pMad
from Peter ten Dijke [49]. Staining was visualized using Alexafluor
488 and 568 anti-mouse, -rabbit, -guinea-pig, or chick secondary
antibodies (Invitrogen; 1:500).
Immunoblotting
Immunoblot analysis of adult heads was carried out using
published methods [50] in conjunction with guinea pig anti-VAP
(1:10,000) and mouse anti-b-tubulin (1:1000; Accurate Chemical
and Scientific).
Image Acquisition and Processing
All confocal images were obtained using a Zeiss Pascal laser
scanning confocal microscope in conjunction with a 63X NA 1.4
Zeiss Apochromat or 40X NA 0.75 Axoplan Neofluar lens at room
temperature using Vectashield (Vector labs) as an imaging
medium and the Zeiss Pascal software. For experiments in which
direct comparisons were made based on fluorescence intensity (i.e.,
Figure 7 and Figure S3) images for different genotypes were
acquired under precisely identical conditions and in succession.
Images were processed in Adobe Photoshop. Films from
immunoblots were scanned with a UMAX Powerlook 1000
transmissive flatbed scanner. Graphical and statistical analyses
were performed using SigmaPlot 9.0 and Systat 3.1.
For quantitation of the relative fluorescence intensity levels of
pMAD, the pixel intensity of pMAD puncta for all three genotypes
(control, G14-GAL4.VAP
wt and G14-GAL4.VAP
P58S) was
measured using Image J software. Three independent sets of
experiments were conducted, and in each case all three genotypes
were imaged simultaneously using identical imaging conditions.
The change in intensity stated in the text represents the average
change observed in these three independent experiments. For each
set, 5–8 synapses of each genotype were imaged. The percentage
relative fluorescence intensity of in G14-GAL4.VAP
wt and G14-
GAL4.VAP
P58S was calculated by normalizing the control
intensity to 100 percent.
Electron Microscopy
Third instar larvae were filleted and pinned first in normal saline,
then glutaraldehyde (2% in 0.12 M sodium cacodylate buffer,
pH 7.4) for 2 hr with rotation. Samples then were rinsed thrice in
0.12 M sodium cacodylate buffer and postfixed with 1% osmium
tetroxide inthe samebuffer with rotation.After postfixation,samples
were washed and stained with 1% aqueous uranyl acetate for 1 hr.
Specimens then were washed, dehydrated, and embedded in
Eponate 12 resin. Thin sections were stained with uranyl acetate
and Sato’s lead. Analysis was carried out using a JEOL 100CX
transmission electron microscope at an operating voltage of 80 kV.
Supporting Information
Figure S1 Comparable expression of UAS-VAP
wt-A1.6 and
UAS-VAP
P58S-A2.1. Immunoblot using head extracts from elav-
GAL4.VAP
wt and elav-GAL4.VAP
P58S animals. The same blot
was stripped and reprobed with anti-b-tubulin.
Found at: doi:10.1371/journal.pone.0002334.s001 (0.69 MB TIF)
Figure S2 A comparison of the cellular staining pattern of VAP
wt
and VAP
P58S in neurons. Shown are images of the 3rd instar larval
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wt (A) and elav-GAL4/VAP
P58S
animals (B). Green, anti-HRP staining; red, anti-VAP. Overex-
pression of VAP
wt leads to robust intracellular staining (A). In
contrast, expression of VAP
P58S leads to formation of aggregates
(B). Scale bar, 10 mm.
Found at: doi:10.1371/journal.pone.0002334.s002 (1.86 MB TIF)
Figure S3 Muscle expression of VAP
wt causes an increase in
pMAD accumulation in neuronal nuclei of the larval CNS. (A–C)
Representative images of the CNS of 3rd instar larvae stained with
an antibody against phophorylated MAD (pMAD) protein. (A)
Control (G14-GAL4/+) animal showing the nuclear accumulation
of phosphorylated MAD. (B) CNS of G14-GAL4/ UAS-VAP
wt
animal. An increase in pMAD staining is observed. (C) CNS of
G14-GAL4/UAS-VAP
P58S animal. A decrease in pMAD staining
is observed. Scale bar, 10 mm.
Found at: doi:10.1371/journal.pone.0002334.s003 (1.13 MB TIF)
Table S1 Analysis of the number of the nc82 immunoreactive
puncta relative to bouton cross sectional area. Values shown are
mean6SEM, N=8 for each genotype; one-way Kruskal-Wallis
ANOVA. There were no significant differences observed,
suggesting that the apparent decrease in the total number of
active zones per synapse might indeed be an effect of reduced
bouton size rather than loss of active zones.
Found at: doi:10.1371/journal.pone.0002334.s004 (0.04 MB
DOC)
Table S2 Quantitation of neurotransmitter vesicle number per
bouton cross sectional area. Values shown are mean6SEM, N=9
for Driver alone and VAPwt and 10 for VAPmut; one-way
ANOVA with Student-Newman-Keuls comparison; each bouton
analyzed was considered as an independent sample for this
analysis irrespective of the animal from which it was obtained.
Neuronal expression of wild type VAP significantly reduced vesicle
numbers as compared to the driver alone or mutant VAP.
Found at: doi:10.1371/journal.pone.0002334.s005 (0.04 MB
DOC)
Table S3 Quantitation of floating T bars per bouton. Values
indicated are mean6SEM, N=16 for Driver alone, 17 for
VAPwt, and 27 for VAPmut; one-way ANOVA with Student-
Newman-Keuls comparison; each bouton analyzed was consid-
ered as an independent sample for this analysis irrespective of the
animal from which it was obtained. Neuronal expression of
mutant VAP significantly increased the number of floating T bars
as compared to the driver alone or mutant VAP.
Found at: doi:10.1371/journal.pone.0002334.s006 (0.04 MB
DOC)
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